<DOC>
	<DOC>NCT00430066</DOC>
	<brief_summary>The purpose of this study is to determine the activity of Glivec 400 mg po daily, as single agent, in inducing a haematological response in Polycythemia Vera. The patients will be asked to have additional bone marrow and blood samples collected: these samples will be used to evaluate how the disease is responding to the drug.</brief_summary>
	<brief_title>Effects of Imatinib Mesylate in Polycythemia Vera</brief_title>
	<detailed_description>Hematocrit &lt;45% in men or &lt;42% in women at 1Â°evaluation within 6 months In case of complete or partial responsiveness, experimental treatment will be continued until 12 months In case of disease progression or treatment failure, experimental drug will be withdrawn and patient will be out of the study</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Diagnosis of Polycythemia Vera requiring treatment with either phlebotomy or Hydroxyurea Age &gt;18 years Signed written informed consent form Pregnancy or breastfeeding Creatinine &gt;3 max NV Bilirubin &gt;3 max NV AST/ALT &gt;3 max NV Concomitant and severe psychiatric disorder Concomitant neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>